Cancer Archives

oxford biotherapeutics drug cancer boehringer

News and Trends 18 Apr 2016

UK Drug Discovery sells Cancer Target to German Pharma

Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database. Oxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell. […]

April 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 18 Apr 2016

Very promising Results for Resistant Lung Cancer

Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival. Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland). One of the hard-to-treat cancers that Ariad is targeting is […]

April 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

nsclc mirati qiagen cancer oncology lung mrna

News and Trends 15 Apr 2016

Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

Qiagen and Mirati will collaborate on the development of a companion diagnostic for a specific type of form of Non-Small Lung Cancer – supporting Mirati’s new therapy. With its operational headquarters near Düsseldorf (Germany), Qiagen is an EU giant in Molecular Diagnostics, and even stepped into the NGS battleground after the acquisition of an important supplier. Qiagen is now entering […]

April 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

labiotech thomas taapken epicolon biotech epigenomics cancer philipp hemme berlin

News and Trends 14 Apr 2016

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Colorectal cancer is the second biggest cancer killer in the US, but Epigenomics could dramatically improve this sad figure. A problem Berlin-based Epigenomics want to solve and just got a significant milestone: an FDA approval for commercialisation. I met with Thomas Taapken, the CEO of the company, in his office in Berlin, a nice historical building with 4 meters ceiling […]

April 14, 2016 - 6 minutesmins - By Philip Hemme

frederic gault coral microbiome interview cancer biotech immunooncology palytoxin adc

News and Trends 14 Apr 2016

Meet the CEO who wants to transform Pretty Corals into therapies for Cancer

The dream of Coral Biome in France is to use marine coral species to develop therapies against Cancer. We had the chance to meet Fréderic Gault, the co-founder and CEO. With an Education in biology followed by a specialism in aquaculture engineering, Fréderic immediately understood the importance of corals and their therapeutic potential in human health. […]

April 14, 2016 - 5 minutesmins - By Marie Godar

xCelligence ols biosciences car t cancer cytotoxicity assay

News and Trends 12 Apr 2016

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T is a groundbreaking personalized cancer therapy with tremendous potential to drive the patient’s own immune cells to specifically target and kill cancer cells. Because the development of this therapy is still in the early phase, new tools are needed to provide a quick potency assay to assess the cytotoxicity of the therapeutic T-cells prior […]

April 12, 2016 - 6 minutesmins - By Jerome Topsent

tunicates pharma mar sea squirt alplidin trial cancer multiple myeloma

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 5 Apr 2016

Israeli Cancer Startup catches Investment from 3 major Big Pharma

Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks. Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

biomoti oncojan physiomics virtual tumor

News and Trends 1 Apr 2016

When Nanoparticles meet Virtual Tumours to build Oncology Platform

BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange. Oxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of […]

April 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Apr 2016

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based. City: Milan (Italy) Founded: 1996 Employees: (+/-) 120 (as of 12/2015) […]

April 1, 2016 - 1 minutemin - By Joachim Eeckhout

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

immunocore uveal melanoma trial imcgp100

News and Trends 31 Mar 2016

Money Magnet Immunocore kicks off Trial for Eye Melanoma

Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone therapy for uveal melanoma, the most common eye cancer. Immunocore is famous for having raised the biggest European Private round ever (€300M), and so it’s no wonder that if often makes our tops here at […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

UK Drug Discovery sells Cancer Target to German Pharma

Very promising Results for Resistant Lung Cancer

Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Meet the CEO who wants to transform Pretty Corals into therapies for Cancer

How CAR-T Cells Kill Cancer: Pictures start Moving

This Successful Phase III Cancer Drug comes from Sea Squirts

Israeli Cancer Startup catches Investment from 3 major Big Pharma

When Nanoparticles meet Virtual Tumours to build Oncology Platform

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Money Magnet Immunocore kicks off Trial for Eye Melanoma

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!